Scpharmaceuticals (NASDAQ:SCPH) Issues Earnings Results

Scpharmaceuticals (NASDAQ:SCPH) announced its earnings results on Tuesday. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.06), MarketWatch Earnings reports.

NASDAQ:SCPH opened at $7.88 on Wednesday. The firm has a 50 day simple moving average of $8.08 and a 200-day simple moving average of $6.16. The company has a debt-to-equity ratio of 0.34, a current ratio of 10.48 and a quick ratio of 10.47. The firm has a market cap of $104.35 million, a PE ratio of -5.40 and a beta of -0.17. Scpharmaceuticals has a 1-year low of $2.44 and a 1-year high of $10.95.

A number of equities analysts have issued reports on the stock. ValuEngine upgraded shares of Scpharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 3rd. Zacks Investment Research cut shares of Scpharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 30th.

In other news, major shareholder Ra Capital Management, L.P. acquired 271,993 shares of the business’s stock in a transaction dated Friday, February 14th. The stock was acquired at an average price of $8.20 per share, with a total value of $2,230,342.60. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.07% of the company’s stock.

Scpharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting.

See Also: Nikkei 225 Index

Earnings History for Scpharmaceuticals (NASDAQ:SCPH)

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with's FREE daily email newsletter.